TransEnterix, Inc. (NYSEAMERICAN:TRXC) rose 8% during trading on Thursday . The stock traded as high as $5.07 and last traded at $4.87. Approximately 8,350,386 shares were traded during trading, an increase of 67% from the average daily volume of 4,985,349 shares. The stock had previously closed at $4.51.
TRXC has been the subject of several research analyst reports. Zacks Investment Research lowered TransEnterix from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Stifel Nicolaus reiterated a “buy” rating and issued a $5.50 target price on shares of TransEnterix in a research note on Thursday, July 5th. Finally, BTIG Research lowered TransEnterix from a “buy” rating to a “neutral” rating in a research note on Thursday, June 28th.
TransEnterix (NYSEAMERICAN:TRXC) last announced its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of $6.39 million for the quarter, compared to the consensus estimate of $6.20 million. TransEnterix had a negative return on equity of 137.69% and a negative net margin of 21,045.36%.
In related news, CFO Joseph P. Slattery sold 4,924 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $7.03, for a total value of $34,615.72. Following the sale, the chief financial officer now directly owns 4,924 shares in the company, valued at approximately $34,615.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joseph P. Slattery sold 64,651 shares of the firm’s stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $5.74, for a total value of $371,096.74. Following the completion of the sale, the chief financial officer now owns 11,951 shares in the company, valued at $68,598.74. The disclosure for this sale can be found here. In the last three months, insiders sold 3,033,622 shares of company stock worth $18,893,751.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new position in shares of TransEnterix during the 2nd quarter valued at $101,000. Amalgamated Bank acquired a new position in shares of TransEnterix during the 2nd quarter valued at $104,000. Ardsley Advisory Partners acquired a new position in shares of TransEnterix during the 2nd quarter valued at $109,000. State Board of Administration of Florida Retirement System acquired a new position in shares of TransEnterix during the 2nd quarter valued at $138,000. Finally, Barclays PLC acquired a new position in shares of TransEnterix during the 1st quarter valued at $164,000.
TransEnterix Company Profile (NYSEAMERICAN:TRXC)
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Further Reading: What is insider trading?
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.